Antigen Discovery, Inc. is a proteomics based biomarker discovery company offering the industry’s leading high throughput protein microarray platform.
Our proteomics-driven approach enables the identification of proteins useful for the development of a wide range of therapeutics, vaccines, and diagnostics.
How We Are Different:
- First company to leverage high throughput proteomics for biomarker discovery.
- Reference laboratory for protein microarray users and manufacturers.
- IP protected platform used to screen the entire proteome and identify relevant antigens
- Expert Statistical Analysis ™ (ESA ™): In over 116 studies, Antigen Discovery’s dedicated
staff of statisticians has validated and tested statistical models and methods to identify protein biomarkers.
- Successful collaborations with industry experts.
- Largest known collection of expressible ORF clones, comprised of over 35,000 biomarker
candidates for infectious agents and more.
- Novel platform accelerates relevant antigen and biomarker discoveries (weeks vs. years).